Molecular Biology Reports

, Volume 39, Issue 2, pp 1079–1086 | Cite as

LDP12, a novel cell-permeable peptide derived from L1 capsid protein of the human papillomavirus



We designed a novel cell-permeable peptide, LDP12, from the human papillomavirus L1 capsid protein. In this work, we examined the mechanism of cellular entry by LDP12 and its efficacy as a potential carrier of protein cargoes. The 12-mer peptide linked to FITC freely enters various types of mammalian cells within a few minutes via an endocytic pathway, as its entry is blocked at a low temperature. Several inhibitors which block certain pathway of endocytosis were used to determine which pathway is utilized by LDP12. We found that methyl-β-cyclodextrin specifically blocks LDP12 entry, suggesting that lipid raft-mediated pathway is involved. Intraluminal injection of LDP12-FITC into the mouse uterus shows that this peptide could penetrate the uterine tissue and stay as long as 24 h. Furthermore, LDP12 with a cysteamide group at the C-terminus successfully carries purified protein cargoes into mammalian cells including rat cortical neurons. Collectively, LDP12 could be utilized as a method of protein therapeutics targeting various mammalian cell types.


Cell-permeable peptide LDP12 Endocytosis Uterus Protein cargo 



This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MEST) (No.2009-0080617). Authors thank Ms. E. B. Park for providing rat neuronal cells. We also thank members of Lim laboratory for various supports.


  1. 1.
    Jarver P, Langel U (2004) The use of cell-penetrating peptides as a tool for gene regulation. Drug Discov Today 9:395–402PubMedGoogle Scholar
  2. 2.
    Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF (1999) In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285:1569–1572PubMedGoogle Scholar
  3. 3.
    Wadia JS, Dowdy SF (2002) Protein transduction technology. Curr Opin Biotechnol 13:52–56PubMedGoogle Scholar
  4. 4.
    Wadia JS, Dowdy SF (2003) Modulation of cellular function by TAT mediated transduction of full length proteins. Curr Protein Pept Sci 4:97–104PubMedGoogle Scholar
  5. 5.
    Zhang MX, Li ZH, Fang YX, Zhu HZ, Xue JL, Chen JZ, Jia W (2009) TAT-phiC31 integrase mediates DNA recombination in mammalian cells. J Biotechnol 142:107–113PubMedGoogle Scholar
  6. 6.
    Pan C, Lu B, Chen H, Bishop CE (2010) Reprogramming human fibroblasts using HIV-1 TAT recombinant proteins OCT4, SOX2, KLF4 and c-MYC. Mol Biol Rep 37:2117–2124PubMedGoogle Scholar
  7. 7.
    Choi JM, Ahn MH, Chae WJ, Jung YG, Park JC, Song HM, Kim YE, Shin JA, Park CS, Park JW, Park TK, Lee JH, Seo BF, Kim KD, Kim ES, Lee DH, Lee SK, Lee SK (2006) Intranasal delivery of the cytoplasmic domain of CTLA-4 using a novel protein transduction domain prevents allergic inflammation. Nat Med 12:574–579PubMedGoogle Scholar
  8. 8.
    Morris MC, Depollier J, Mery J, Heitz F, Divita G (2001) A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 19:1173–1176PubMedGoogle Scholar
  9. 9.
    Weller K, Lauber S, Lerch M, Renaud A, Merkle HP, Zerbe O (2005) Biophysical and biological studies of end-group-modified derivatives of Pep-1. Biochemistry 44:15799–15811PubMedGoogle Scholar
  10. 10.
    Morris MC, Vidal P, Chaloin L, Heitz F, Divita G (1997) A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 25:2730–2736PubMedGoogle Scholar
  11. 11.
    Fittipaldi A, Ferrari A, Zoppe M, Arcangeli C, Pellegrini V, Beltram F, Giacca M (2003) Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 278:34141–34149PubMedGoogle Scholar
  12. 12.
    Nakase I, Niwa M, Takeuchi T, Sonomura K, Kawabata N, Koike Y, Takehashi M, Tanaka S, Ueda K, Simpson JC, Jones AT, Sugiura Y, Futaki S (2004) Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 10:1011–1022PubMedGoogle Scholar
  13. 13.
    Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310–315PubMedGoogle Scholar
  14. 14.
    Fretz MM, Penning NA, Al-Taei S, Futaki S, Takeuchi T, Nakase I, Storm G, Jones AT (2007) Temperature-, concentration- and cholesterol-dependent translocation of L- and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J 403:335–342PubMedGoogle Scholar
  15. 15.
    Gerbal-Chaloin S, Gondeau C, drian-Herrada G, Heitz F, Gauthier-Rouviere C, Divita G (2007) First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actin-network remodelling. Biol Cell 99:223–238PubMedGoogle Scholar
  16. 16.
    Kwon SJ, Han K, Jung S, Lee JE, Park S, Cheon YP, Lim HJ (2009) Transduction of the MPG-tagged fusion protein into mammalian cells and oocytes depends on amiloride-sensitive endocytic pathway. BMC Biotechnol 9:73PubMedGoogle Scholar
  17. 17.
    Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, Jansen KU, Keller PM (1999) The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274:5810–5822PubMedGoogle Scholar
  18. 18.
    Sasagawa T, Pushko P, Steers G, Gschmeissner SE, Hajibagheri MA, Finch J, Crawford L, Tommasino M (1995) Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206:126–135PubMedGoogle Scholar
  19. 19.
    Windram OP, Weber B, Jaffer MA, Rybicki EP, Shepherd DN, Varsani A (2008) An investigation into the use of human papillomavirus type 16 virus-like particles as a delivery vector system for foreign proteins: N- and C-terminal fusion of GFP to the L1 and L2 capsid proteins. Arch Virol 153:585–589PubMedGoogle Scholar
  20. 20.
    Hindmarsh PL, Laimins LA (2007) Mechanisms regulating expression of the HPV 31 L1 and L2 capsid proteins and pseudovirion entry. Virol J 4:19PubMedGoogle Scholar
  21. 21.
    Lee HJ, Khoshaghideh F, Patel S, Lee SJ (2004) Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 24:1888–1896PubMedGoogle Scholar
  22. 22.
    Kameyama S, Horie M, Kikuchi T, Omura T, Tadokoro A, Takeuchi T, Nakase I, Sugiura Y, Futaki S (2007) Acid wash in determining cellular uptake of Fab/cell-permeating peptide conjugates. Biopolymers 88:98–107PubMedGoogle Scholar
  23. 23.
    Becker-Hapak M, McAllister SS, Dowdy SF (2001) TAT-mediated protein transduction into mammalian cells. Methods 24:247–256PubMedGoogle Scholar
  24. 24.
    Nagy A, Gertsenstein M, Vintersten K, Behringer R (2003) Manipulating the mouse embryo. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New YorkGoogle Scholar
  25. 25.
    Conner SD, Schmid SL (2003) Regulated portals of entry into the cell. Nature 422:37–44PubMedGoogle Scholar
  26. 26.
    West MA, Bretscher MS, Watts C (1989) Distinct endocytotic pathways in epidermal growth factor-stimulated human carcinoma A431 cells. J Cell Biol 109:2731–2739PubMedGoogle Scholar
  27. 27.
    Hao M, Mukherjee S, Sun Y, Maxfield FR (2004) Effects of cholesterol depletion and increased lipid unsaturation on the properties of endocytic membranes. J Biol Chem 279:14171–14178PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  1. 1.Department of Biomedical Science and TechnologySMART Institute of Advanced Biomedical Science, RCTC, Konkuk UniversitySeoulKorea

Personalised recommendations